Total Payments
$35,143
2024 Payments
$1,751
Companies
44
Transactions
502
Medicare Patients
5,952
Medicare Billing
$532,018
Payment Breakdown by Category
Research$23,316 (66.3%)
Food & Beverage$10,756 (30.6%)
Travel$969.62 (2.8%)
Education$101.87 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,316 | 8 | 66.3% |
| Food and Beverage | $10,756 | 489 | 30.6% |
| Travel and Lodging | $969.62 | 3 | 2.8% |
| Education | $101.87 | 2 | 0.3% |
Payments by Type
Research
$23,316
8 transactions
General
$11,827
494 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $17,566 | 7 | $0 (2022) |
| PFIZER INC. | $7,717 | 50 | $0 (2024) |
| ABBVIE INC. | $1,664 | 94 | $0 (2024) |
| Allergan, Inc. | $890.47 | 49 | $0 (2022) |
| Lilly USA, LLC | $866.33 | 45 | $0 (2024) |
| Merz North America, Inc. | $754.83 | 10 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $751.75 | 34 | $0 (2024) |
| Janssen Biotech, Inc. | $724.84 | 29 | $0 (2024) |
| Amgen Inc. | $629.96 | 27 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $526.08 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,751 | 82 | ABBVIE INC. ($369.59) |
| 2023 | $8,675 | 70 | PFIZER INC. ($7,201) |
| 2022 | $1,550 | 63 | Merz North America, Inc. ($278.97) |
| 2021 | $6,141 | 49 | Eli Lilly and Company ($5,172) |
| 2020 | $7,971 | 47 | Eli Lilly and Company ($7,102) |
| 2019 | $7,114 | 81 | Eli Lilly and Company ($5,261) |
| 2018 | $1,238 | 68 | Merz North America, Inc. ($239.28) |
| 2017 | $702.73 | 42 | Allergan Inc. ($133.04) |
All Payment Transactions
502 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Dermatology | ||||||
| 12/12/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $35.29 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $4.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: DERMATOLOGY | ||||||
| 12/04/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $24.58 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Dermatology | ||||||
| 11/06/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: Inflammation | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $21.95 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: Dermatology | ||||||
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $2.29 | General |
| 10/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $29.31 | General |
| Category: Inflammation | ||||||
| 10/08/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $17.55 | General |
| Category: Dermatology | ||||||
| 10/02/2024 | Almirall LLC | Klisyri (Drug) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Dermatology | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.85 | General |
| Category: Dermatology | ||||||
| 09/30/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: FACIAL AESTHETICS | ||||||
| 09/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Immunology | ||||||
| 09/25/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: FACIAL AESTHETICS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $10,463 | 4 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $7,103 | 3 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $5,750 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,859 | 3,343 | $366,150 | $137,167 |
| 2022 | 18 | 1,513 | 2,572 | $308,060 | $117,209 |
| 2021 | 17 | 1,279 | 2,175 | $255,503 | $99,318 |
| 2020 | 23 | 1,301 | 3,034 | $420,626 | $178,325 |
Total Patients
5,952
Total Services
11,124
Medicare Billing
$532,018
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 432 | 569 | $87,347 | $33,598 | 38.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 301 | 426 | $48,660 | $16,297 | 33.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 181 | 215 | $37,151 | $14,547 | 39.2% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 22 | 28 | $32,250 | $12,423 | 38.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 177 | 227 | $21,766 | $8,608 | 39.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 127 | 127 | $24,137 | $8,343 | 34.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 70 | 89 | $17,188 | $7,062 | 41.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 244 | 1,295 | $14,733 | $6,309 | 42.8% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 19 | 23 | $18,491 | $6,088 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 68 | $14,756 | $5,428 | 36.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 36 | 43 | $13,105 | $5,164 | 39.4% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 13 | 13 | $9,449 | $3,700 | 39.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 50 | 81 | $6,937 | $3,057 | 44.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 55 | 55 | $6,760 | $2,305 | 34.1% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 12 | 13 | $2,783 | $1,168 | 42.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 13 | 13 | $2,775 | $1,080 | 38.9% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 11 | $4,592 | $1,051 | 22.9% |
| 69100 | Biopsy of ear | Office | 2023 | 13 | 15 | $2,470 | $754.00 | 30.5% |
| Q0112 | All potassium hydroxide (koh) preparations | Office | 2023 | 25 | 32 | $800.00 | $182.73 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 331 | 418 | $64,790 | $24,963 | 38.5% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 28 | 32 | $36,883 | $14,605 | 39.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 229 | 306 | $35,248 | $12,269 | 34.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 145 | 170 | $30,027 | $11,420 | 38.0% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2022 | 30 | 30 | $24,453 | $7,326 | 30.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 92 | 92 | $17,555 | $7,085 | 40.4% |
About Timothy Rodgers
Timothy Rodgers is a Pediatric Dermatology healthcare provider based in Frisco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255395067.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Timothy Rodgers has received a total of $35,143 in payments from pharmaceutical and medical device companies, with $1,751 received in 2024. These payments were reported across 502 transactions from 44 companies. The most common payment nature is "" ($23,316).
As a Medicare-enrolled provider, Rodgers has provided services to 5,952 Medicare beneficiaries, totaling 11,124 services with total Medicare billing of $532,018. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Procedural Dermatology, MOHS-Micrographic Surgery
- Location Frisco, TX
- Active Since 04/17/2006
- Last Updated 09/18/2024
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1255395067
Products in Payments
- NURTEC ODT (Drug) $5,750
- TALTZ (Drug) $838.77
- EUCRISA (Drug) $560.03
- Otezla (Drug) $557.75
- BOTOX (Biological) $553.54
- SKYRIZI (Biological) $540.13
- Humira (Biological) $454.71
- COSENTYX (Biological) $424.25
- TREMFYA (Drug) $360.47
- COSENTYX (Drug) $247.83
- RINVOQ (Biological) $209.30
- DUPIXENT (Biological) $189.63
- OPZELURA (Drug) $178.02
- Xeomin (Biological) $173.00
- Tremfya (Drug) $160.06
- SOOLANTRA (Drug) $155.63
- BOTOX COSMETIC (Biological) $151.54
- DORYX (Drug) $128.78
- ILUMYA (Biological) $116.09
- STELARA (Biological) $108.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.